ID   UBP8_HUMAN              Reviewed;        1118 AA.
AC   P40818; B4DKA8; Q2TB31; Q7Z3U2; Q86VA0; Q8IWI7;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   10-MAY-2017, entry version 186.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase 8;
DE            EC=3.4.19.12 {ECO:0000269|PubMed:9628861};
DE   AltName: Full=Deubiquitinating enzyme 8;
DE   AltName: Full=Ubiquitin isopeptidase Y;
DE            Short=hUBPy;
DE   AltName: Full=Ubiquitin thioesterase 8;
DE   AltName: Full=Ubiquitin-specific-processing protease 8;
GN   Name=USP8; Synonyms=KIAA0055, UBPY;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S.,
RA   Seki N., Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II.
RT   The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INDUCTION.
RX   PubMed=9628861; DOI=10.1093/emboj/17.12.3241;
RA   Naviglio S., Mattecucci C., Matoskova B., Nagase T., Nomura N.,
RA   Di Fiore P.P., Draetta G.F.;
RT   "UBPY: a growth-regulated human ubiquitin isopeptidase.";
RL   EMBO J. 17:3241-3250(1998).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-786.
RX   PubMed=16520378; DOI=10.1074/jbc.M512615200;
RA   Row P.E., Prior I.A., McCullough J., Clague M.J., Urbe S.;
RT   "The ubiquitin isopeptidase UBPY regulates endosomal ubiquitin
RT   dynamics and is essential for receptor down-regulation.";
RL   J. Biol. Chem. 281:12618-12624(2006).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [9]
RP   DOMAIN, INTERACTION WITH CHMP1A; CHMP1B AND CHMP7, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=17711858; DOI=10.1074/jbc.M704009200;
RA   Row P.E., Liu H., Hayes S., Welchman R., Charalabous P., Hofmann K.,
RA   Clague M.J., Sanderson C.M., Urbe S.;
RT   "The MIT domain of UBPY constitutes a CHMP binding and endosomal
RT   localization signal required for efficient epidermal growth factor
RT   receptor degradation.";
RL   J. Biol. Chem. 282:30929-30937(2007).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH BIRC6/BRUCE AND KIF23/MKLP1.
RX   PubMed=18329369; DOI=10.1016/j.cell.2008.01.012;
RA   Pohl C., Jentsch S.;
RT   "Final stages of cytokinesis and midbody ring formation are controlled
RT   by BRUCE.";
RL   Cell 132:832-845(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-452; SER-718 AND
RP   SER-719, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   INTERACTION WITH NBR1, AND SUBCELLULAR LOCATION.
RX   PubMed=19427866; DOI=10.1016/j.febslet.2009.04.049;
RA   Waters S., Marchbank K., Solomon E., Whitehouse C., Gautel M.;
RT   "Interactions with LC3 and polyubiquitin chains link nbr1 to
RT   autophagic protein turnover.";
RL   FEBS Lett. 583:1846-1852(2009).
RN   [14]
RP   INTERACTION WITH IST1.
RX   PubMed=19129480; DOI=10.1091/mbc.E08-05-0474;
RA   Agromayor M., Carlton J.G., Phelan J.P., Matthews D.R., Carlin L.M.,
RA   Ameer-Beg S., Bowers K., Martin-Serrano J.;
RT   "Essential role of hIST1 in cytokinesis.";
RL   Mol. Biol. Cell 20:1374-1387(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-160 AND SER-718, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-577 AND SER-718, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-160; SER-392; SER-400;
RP   SER-452; THR-577 AND SER-718, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   STRUCTURE BY NMR OF 174-317.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the rhodanese-like domain in human ubiquitin
RT   specific protease 8 (UBP8).";
RL   Submitted (NOV-2004) to the PDB data bank.
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 181-318 IN COMPLEX WITH
RP   RNF41.
RX   PubMed=17035239; DOI=10.1074/jbc.M606704200;
RA   Avvakumov G.V., Walker J.R., Xue S., Finerty P.J. Jr., Mackenzie F.,
RA   Newman E.M., Dhe-Paganon S.;
RT   "Amino-terminal dimerization, NRDP1-rhodanese interaction, and
RT   inhibited catalytic domain conformation of the ubiquitin-specific
RT   protease 8 (USP8).";
RL   J. Biol. Chem. 281:38061-38070(2006).
RN   [23]
RP   VARIANT LYS-310.
RX   PubMed=24482476; DOI=10.1126/science.1247363;
RA   Novarino G., Fenstermaker A.G., Zaki M.S., Hofree M., Silhavy J.L.,
RA   Heiberg A.D., Abdellateef M., Rosti B., Scott E., Mansour L.,
RA   Masri A., Kayserili H., Al-Aama J.Y., Abdel-Salam G.M., Karminejad A.,
RA   Kara M., Kara B., Bozorgmehri B., Ben-Omran T., Mojahedi F.,
RA   Mahmoud I.G., Bouslam N., Bouhouche A., Benomar A., Hanein S.,
RA   Raymond L., Forlani S., Mascaro M., Selim L., Shehata N.,
RA   Al-Allawi N., Bindu P.S., Azam M., Gunel M., Caglayan A., Bilguvar K.,
RA   Tolun A., Issa M.Y., Schroth J., Spencer E.G., Rosti R.O., Akizu N.,
RA   Vaux K.K., Johansen A., Koh A.A., Megahed H., Durr A., Brice A.,
RA   Stevanin G., Gabriel S.B., Ideker T., Gleeson J.G.;
RT   "Exome sequencing links corticospinal motor neuron disease to common
RT   neurodegenerative disorders.";
RL   Science 343:506-511(2014).
CC   -!- FUNCTION: Hydrolase that can remove conjugated ubiquitin from
CC       proteins and therefore plays an important regulatory role at the
CC       level of protein turnover by preventing degradation. Converts both
CC       'Lys-48' an 'Lys-63'-linked ubiquitin chains. Catalytic activity
CC       is enhanced in the M phase. Involved in cell proliferation.
CC       Required to enter into S phase in response to serum stimulation.
CC       May regulate T-cell anergy mediated by RNF128 via the formation of
CC       a complex containing RNF128 and OTUB1. Probably regulates the
CC       stability of STAM2 and RASGRF1. Regulates endosomal ubiquitin
CC       dynamics, cargo sorting, membrane traffic at early endosomes, and
CC       maintenance of ESCRT-0 stability. The level of protein
CC       ubiquitination on endosomes is essential for maintaining the
CC       morphology of the organelle. Deubiquitinates EPS15 and controles
CC       tyrosine kinase stability. Removes conjugated ubiquitin from EGFR
CC       thus regulating EGFR degradation and downstream MAPK signaling.
CC       Involved in acrosome biogenesis through interaction with the
CC       spermatid ESCRT-0 complex and microtubules. Deubiquitinates
CC       BIRC6/bruce and KIF23/MKLP1. {ECO:0000269|PubMed:16520378,
CC       ECO:0000269|PubMed:17711858, ECO:0000269|PubMed:18329369,
CC       ECO:0000269|PubMed:9628861}.
CC   -!- CATALYTIC ACTIVITY: Thiol-dependent hydrolysis of ester,
CC       thioester, amide, peptide and isopeptide bonds formed by the C-
CC       terminal Gly of ubiquitin (a 76-residue protein attached to
CC       proteins as an intracellular targeting signal).
CC       {ECO:0000269|PubMed:9628861}.
CC   -!- SUBUNIT: Forms a ternary complex with RNF128 and OTUB1. Interacts
CC       (via C-terminal UCH catalytic domain) with OTUB1 isoform 1.
CC       Interacts with STAM2 (via SH3 domain). Interacts with DNAJB3,
CC       EGFR, EPS15, RASGRF1, RNF41, YWHAE, YWHAG and YWHAZ (By
CC       similarity). Interacts with NBR1, RASGRF1, RNF41 and IST1.
CC       Associates with the ESCRT-0 complex and with microtubules (By
CC       similarity). Interacts with BIRC6/bruce and KIF23/MKLP1.
CC       {ECO:0000250, ECO:0000269|PubMed:17035239,
CC       ECO:0000269|PubMed:17711858, ECO:0000269|PubMed:18329369,
CC       ECO:0000269|PubMed:19129480, ECO:0000269|PubMed:19427866}.
CC   -!- INTERACTION:
CC       Q9HD42:CHMP1A; NbExp=3; IntAct=EBI-1050865, EBI-1057156;
CC       Q7LBR1:CHMP1B; NbExp=5; IntAct=EBI-1050865, EBI-2118090;
CC       Q96CF2:CHMP4C; NbExp=2; IntAct=EBI-1050865, EBI-1221015;
CC       Q99814:EPAS1; NbExp=2; IntAct=EBI-1050865, EBI-447470;
CC       Q16665:HIF1A; NbExp=2; IntAct=EBI-1050865, EBI-447269;
CC       Q14596:NBR1; NbExp=3; IntAct=EBI-1050865, EBI-742698;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16520378,
CC       ECO:0000269|PubMed:17711858, ECO:0000269|PubMed:19427866}. Nucleus
CC       {ECO:0000250|UniProtKB:Q80U87}. Endosome membrane
CC       {ECO:0000269|PubMed:16520378, ECO:0000269|PubMed:17711858};
CC       Peripheral membrane protein {ECO:0000305}. Cell membrane
CC       {ECO:0000269|PubMed:16520378}; Peripheral membrane protein
CC       {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P40818-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P40818-2; Sequence=VSP_054594, VSP_054595;
CC         Note=No experimental confirmation available.;
CC   -!- INDUCTION: Upon growth stimulation in starved human fibroblasts.
CC       Decreases in response to growth arrest induced by cell-cell
CC       contact. {ECO:0000269|PubMed:9628861}.
CC   -!- DOMAIN: The MIT domain is required for endosomal localization,
CC       CHMP1B-binding, maintenance of ESCRT-0 stability and EGFR
CC       degradation. {ECO:0000269|PubMed:17711858}.
CC   -!- DOMAIN: The rhodanese domain is sufficient for RNF41-binding.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation of Ser-718 is essential for interaction with
CC       YWHAE and for cytosol localization. Undergoes dephosphorylation at
CC       Ser-718 in the M phase. Tyrosine-phosphorylated in its N-terminal
CC       half in an EGFR-dependent manner. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Inactive form is mostly monoubiquitinated, but
CC       polyubiquitination happens too. Ubiquitination is increased in
CC       EGF-stimulated cells. Ubiquitination of active form is
CC       undetectable, suggesting a possibility that USP8 deubiquitinates
CC       itself, thereby regulating its own function (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH38801.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH51345.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D29956; BAA06225.2; -; mRNA.
DR   EMBL; AK296480; BAG59120.1; -; mRNA.
DR   EMBL; BX537420; CAD97662.1; -; mRNA.
DR   EMBL; AC012170; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC038801; AAH38801.1; ALT_SEQ; mRNA.
DR   EMBL; BC051345; AAH51345.1; ALT_SEQ; mRNA.
DR   EMBL; BC110590; AAI10591.1; -; mRNA.
DR   CCDS; CCDS10137.1; -. [P40818-1]
DR   CCDS; CCDS61632.1; -. [P40818-2]
DR   RefSeq; NP_001122082.1; NM_001128610.2. [P40818-1]
DR   RefSeq; NP_001269978.1; NM_001283049.1. [P40818-2]
DR   RefSeq; NP_005145.3; NM_005154.4. [P40818-1]
DR   RefSeq; XP_006720824.1; XM_006720761.3. [P40818-1]
DR   RefSeq; XP_011520495.1; XM_011522193.2. [P40818-1]
DR   UniGene; Hs.443731; -.
DR   PDB; 1WHB; NMR; -; A=174-317.
DR   PDB; 2A9U; X-ray; 2.10 A; A/B=1-142.
DR   PDB; 2GFO; X-ray; 2.00 A; A=734-1110.
DR   PDB; 2GWF; X-ray; 2.30 A; A/C/E=181-318.
DR   PDB; 3N3K; X-ray; 2.60 A; A=734-1110.
DR   PDBsum; 1WHB; -.
DR   PDBsum; 2A9U; -.
DR   PDBsum; 2GFO; -.
DR   PDBsum; 2GWF; -.
DR   PDBsum; 3N3K; -.
DR   ProteinModelPortal; P40818; -.
DR   SMR; P40818; -.
DR   BioGrid; 114555; 75.
DR   DIP; DIP-40365N; -.
DR   IntAct; P40818; 24.
DR   MINT; MINT-244406; -.
DR   STRING; 9606.ENSP00000302239; -.
DR   BindingDB; P40818; -.
DR   ChEMBL; CHEMBL2157854; -.
DR   MEROPS; C19.011; -.
DR   iPTMnet; P40818; -.
DR   PhosphoSitePlus; P40818; -.
DR   BioMuta; USP8; -.
DR   DMDM; 731046; -.
DR   EPD; P40818; -.
DR   MaxQB; P40818; -.
DR   PaxDb; P40818; -.
DR   PeptideAtlas; P40818; -.
DR   PRIDE; P40818; -.
DR   Ensembl; ENST00000307179; ENSP00000302239; ENSG00000138592. [P40818-1]
DR   Ensembl; ENST00000396444; ENSP00000379721; ENSG00000138592. [P40818-1]
DR   Ensembl; ENST00000425032; ENSP00000412682; ENSG00000138592. [P40818-2]
DR   GeneID; 9101; -.
DR   KEGG; hsa:9101; -.
DR   UCSC; uc001zyl.6; human. [P40818-1]
DR   CTD; 9101; -.
DR   DisGeNET; 9101; -.
DR   GeneCards; USP8; -.
DR   H-InvDB; HIX0172812; -.
DR   HGNC; HGNC:12631; USP8.
DR   HPA; HPA004869; -.
DR   HPA; HPA050215; -.
DR   MalaCards; USP8; -.
DR   MIM; 603158; gene.
DR   neXtProt; NX_P40818; -.
DR   OpenTargets; ENSG00000138592; -.
DR   Orphanet; 401795; Autosomal recessive spastic paraplegia type 59.
DR   PharmGKB; PA37256; -.
DR   eggNOG; KOG1868; Eukaryota.
DR   eggNOG; ENOG410XP8T; LUCA.
DR   GeneTree; ENSGT00860000133682; -.
DR   HOGENOM; HOG000231497; -.
DR   HOVERGEN; HBG012631; -.
DR   InParanoid; P40818; -.
DR   KO; K11839; -.
DR   OMA; YKCVASR; -.
DR   OrthoDB; EOG091G0120; -.
DR   PhylomeDB; P40818; -.
DR   TreeFam; TF106277; -.
DR   BRENDA; 3.4.19.12; 2681.
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; R-HSA-4641263; Regulation of FZD by ubiquitination.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-6807004; Negative regulation of MET activity.
DR   SignaLink; P40818; -.
DR   ChiTaRS; USP8; human.
DR   EvolutionaryTrace; P40818; -.
DR   GeneWiki; USP8; -.
DR   GenomeRNAi; 9101; -.
DR   PRO; PR:P40818; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000138592; -.
DR   CleanEx; HS_USP8; -.
DR   ExpressionAtlas; P40818; baseline and differential.
DR   Genevisible; P40818; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0031313; C:extrinsic component of endosome membrane; IBA:GO_Central.
DR   GO; GO:0019897; C:extrinsic component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030496; C:midbody; IDA:MGI.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; TAS:ProtInc.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0004843; F:thiol-dependent ubiquitin-specific protease activity; IDA:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007032; P:endosome organization; IMP:UniProtKB.
DR   GO; GO:0000281; P:mitotic cytokinesis; IMP:MGI.
DR   GO; GO:0016579; P:protein deubiquitination; IMP:MGI.
DR   GO; GO:0071108; P:protein K48-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0070536; P:protein K63-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   Gene3D; 3.40.250.10; -; 1.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR001763; Rhodanese-like_dom.
DR   InterPro; IPR015063; USP8_dimer.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   Pfam; PF00581; Rhodanese; 1.
DR   Pfam; PF00443; UCH; 1.
DR   Pfam; PF08969; USP8_dimer; 1.
DR   SUPFAM; SSF52821; SSF52821; 1.
DR   PROSITE; PS50206; RHODANESE_3; 1.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Cell membrane;
KW   Complete proteome; Cytoplasm; Endosome; Hydrolase; Membrane; Nucleus;
KW   Phosphoprotein; Polymorphism; Protease; Reference proteome;
KW   SH3-binding; Thiol protease; Ubl conjugation; Ubl conjugation pathway.
FT   CHAIN         1   1118       Ubiquitin carboxyl-terminal hydrolase 8.
FT                                /FTId=PRO_0000080627.
FT   DOMAIN       33    116       MIT.
FT   DOMAIN      195    313       Rhodanese. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00173}.
FT   DOMAIN      777   1109       USP.
FT   MOTIF       405    413       SH3-binding. {ECO:0000250}.
FT   ACT_SITE    786    786       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092, ECO:0000255|PROSITE-
FT                                ProRule:PRU10093}.
FT   ACT_SITE   1067   1067       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092, ECO:0000255|PROSITE-
FT                                ProRule:PRU10093}.
FT   MOD_RES     160    160       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     392    392       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     400    400       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     452    452       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     577    577       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     718    718       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     719    719       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     945    945       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q80U87}.
FT   VAR_SEQ      35    111       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054594.
FT   VAR_SEQ     601    629       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054595.
FT   VARIANT     310    310       Q -> K (found in a patient with spastic
FT                                paraplegia; unknown pathological
FT                                significance; dbSNP:rs587777201).
FT                                {ECO:0000269|PubMed:24482476}.
FT                                /FTId=VAR_077850.
FT   VARIANT     443    443       D -> G (in dbSNP:rs3743044).
FT                                /FTId=VAR_017796.
FT   VARIANT     739    739       T -> A (in dbSNP:rs11638390).
FT                                /FTId=VAR_051525.
FT   VARIANT     827    827       A -> G (in dbSNP:rs1056577).
FT                                /FTId=VAR_017797.
FT   MUTAGEN     786    786       C->S: Impairs deubiquitination activity
FT                                and leads to endosome membrane
FT                                accumulation.
FT                                {ECO:0000269|PubMed:16520378}.
FT   CONFLICT    526    526       E -> G (in Ref. 3; CAD97662).
FT                                {ECO:0000305}.
FT   CONFLICT    717    717       Y -> H (in Ref. 3; CAD97662).
FT                                {ECO:0000305}.
FT   CONFLICT    945    945       T -> A (in Ref. 3; CAD97662).
FT                                {ECO:0000305}.
FT   HELIX        17     21       {ECO:0000244|PDB:2A9U}.
FT   HELIX        22     24       {ECO:0000244|PDB:2A9U}.
FT   HELIX        28     30       {ECO:0000244|PDB:2A9U}.
FT   HELIX        33     52       {ECO:0000244|PDB:2A9U}.
FT   HELIX        56     73       {ECO:0000244|PDB:2A9U}.
FT   HELIX        77     81       {ECO:0000244|PDB:2A9U}.
FT   HELIX        83     90       {ECO:0000244|PDB:2A9U}.
FT   HELIX        92    138       {ECO:0000244|PDB:2A9U}.
FT   STRAND      181    183       {ECO:0000244|PDB:1WHB}.
FT   HELIX       185    193       {ECO:0000244|PDB:2GWF}.
FT   STRAND      195    197       {ECO:0000244|PDB:1WHB}.
FT   STRAND      199    203       {ECO:0000244|PDB:2GWF}.
FT   HELIX       207    212       {ECO:0000244|PDB:2GWF}.
FT   STRAND      219    221       {ECO:0000244|PDB:1WHB}.
FT   HELIX       223    225       {ECO:0000244|PDB:2GWF}.
FT   HELIX       232    237       {ECO:0000244|PDB:2GWF}.
FT   HELIX       241    248       {ECO:0000244|PDB:2GWF}.
FT   TURN        249    252       {ECO:0000244|PDB:2GWF}.
FT   STRAND      253    259       {ECO:0000244|PDB:2GWF}.
FT   HELIX       265    267       {ECO:0000244|PDB:2GWF}.
FT   HELIX       273    282       {ECO:0000244|PDB:2GWF}.
FT   STRAND      295    297       {ECO:0000244|PDB:2GWF}.
FT   HELIX       300    307       {ECO:0000244|PDB:2GWF}.
FT   HELIX       309    311       {ECO:0000244|PDB:2GWF}.
FT   HELIX       763    765       {ECO:0000244|PDB:2GFO}.
FT   STRAND      782    784       {ECO:0000244|PDB:2GFO}.
FT   HELIX       786    796       {ECO:0000244|PDB:2GFO}.
FT   HELIX       799    806       {ECO:0000244|PDB:2GFO}.
FT   TURN        807    809       {ECO:0000244|PDB:2GFO}.
FT   HELIX       810    813       {ECO:0000244|PDB:2GFO}.
FT   HELIX       825    839       {ECO:0000244|PDB:2GFO}.
FT   STRAND      842    845       {ECO:0000244|PDB:2GFO}.
FT   HELIX       848    857       {ECO:0000244|PDB:2GFO}.
FT   HELIX       859    861       {ECO:0000244|PDB:2GFO}.
FT   STRAND      862    865       {ECO:0000244|PDB:2GFO}.
FT   HELIX       869    884       {ECO:0000244|PDB:2GFO}.
FT   HELIX       903    917       {ECO:0000244|PDB:2GFO}.
FT   HELIX       921    926       {ECO:0000244|PDB:2GFO}.
FT   STRAND      928    936       {ECO:0000244|PDB:2GFO}.
FT   TURN        937    939       {ECO:0000244|PDB:2GFO}.
FT   STRAND      942    954       {ECO:0000244|PDB:2GFO}.
FT   STRAND      959    963       {ECO:0000244|PDB:2GFO}.
FT   HELIX       964    971       {ECO:0000244|PDB:2GFO}.
FT   STRAND      975    977       {ECO:0000244|PDB:2GFO}.
FT   HELIX       979    981       {ECO:0000244|PDB:3N3K}.
FT   STRAND      983    985       {ECO:0000244|PDB:2GFO}.
FT   TURN        986    989       {ECO:0000244|PDB:2GFO}.
FT   STRAND      990    992       {ECO:0000244|PDB:2GFO}.
FT   STRAND      994   1002       {ECO:0000244|PDB:2GFO}.
FT   STRAND     1005   1011       {ECO:0000244|PDB:2GFO}.
FT   STRAND     1014   1016       {ECO:0000244|PDB:2GFO}.
FT   STRAND     1018   1023       {ECO:0000244|PDB:2GFO}.
FT   STRAND     1027   1029       {ECO:0000244|PDB:2GFO}.
FT   HELIX      1038   1040       {ECO:0000244|PDB:2GFO}.
FT   STRAND     1051   1061       {ECO:0000244|PDB:2GFO}.
FT   TURN       1063   1065       {ECO:0000244|PDB:2GFO}.
FT   STRAND     1067   1074       {ECO:0000244|PDB:2GFO}.
FT   TURN       1075   1078       {ECO:0000244|PDB:2GFO}.
FT   STRAND     1079   1084       {ECO:0000244|PDB:2GFO}.
FT   STRAND     1087   1090       {ECO:0000244|PDB:2GFO}.
FT   HELIX      1093   1095       {ECO:0000244|PDB:2GFO}.
FT   STRAND     1101   1107       {ECO:0000244|PDB:2GFO}.
SQ   SEQUENCE   1118 AA;  127523 MW;  8B884B7A842F9A9A CRC64;
     MPAVASVPKE LYLSSSLKDL NKKTEVKPEK ISTKSYVHSA LKIFKTAEEC RLDRDEERAY
     VLYMKYVTVY NLIKKRPDFK QQQDYFHSIL GPGNIKKAVE EAERLSESLK LRYEEAEVRK
     KLEEKDRQEE AQRLQQKRQE TGREDGGTLA KGSLENVLDS KDKTQKSNGE KNEKCETKEK
     GAITAKELYT MMTDKNISLI IMDARRMQDY QDSCILHSLS VPEEAISPGV TASWIEAHLP
     DDSKDTWKKR GNVEYVVLLD WFSSAKDLQI GTTLRSLKDA LFKWESKTVL RNEPLVLEGG
     YENWLLCYPQ YTTNAKVTPP PRRQNEEVSI SLDFTYPSLE ESIPSKPAAQ TPPASIEVDE
     NIELISGQNE RMGPLNISTP VEPVAASKSD VSPIIQPVPS IKNVPQIDRT KKPAVKLPEE
     HRIKSESTNH EQQSPQSGKV IPDRSTKPVV FSPTLMLTDE EKARIHAETA LLMEKNKQEK
     ELRERQQEEQ KEKLRKEEQE QKAKKKQEAE ENEITEKQQK AKEEMEKKES EQAKKEDKET
     SAKRGKEITG VKRQSKSEHE TSDAKKSVED RGKRCPTPEI QKKSTGDVPH TSVTGDSGSG
     KPFKIKGQPE SGILRTGTFR EDTDDTERNK AQREPLTRAR SEEMGRIVPG LPSGWAKFLD
     PITGTFRYYH SPTNTVHMYP PEMAPSSAPP STPPTHKAKP QIPAERDREP SKLKRSYSSP
     DITQAIQEEE KRKPTVTPTV NRENKPTCYP KAEISRLSAS QIRNLNPVFG GSGPALTGLR
     NLGNTCYMNS ILQCLCNAPH LADYFNRNCY QDDINRSNLL GHKGEVAEEF GIIMKALWTG
     QYRYISPKDF KITIGKINDQ FAGYSQQDSQ ELLLFLMDGL HEDLNKADNR KRYKEENNDH
     LDDFKAAEHA WQKHKQLNES IIVALFQGQF KSTVQCLTCH KKSRTFEAFM YLSLPLASTS
     KCTLQDCLRL FSKEEKLTDN NRFYCSHCRA RRDSLKKIEI WKLPPVLLVH LKRFSYDGRW
     KQKLQTSVDF PLENLDLSQY VIGPKNNLKK YNLFSVSNHY GGLDGGHYTA YCKNAARQRW
     FKFDDHEVSD ISVSSVKSSA AYILFYTSLG PRVTDVAT
//
